Lupus drug sirolimus shows promise in phase 3 trial
NCT ID NCT04582136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding sirolimus (rapamycin) to standard treatment helps control active lupus better than placebo. 146 adults with active lupus despite standard care will receive either sirolimus or placebo for 24 weeks, with an option to continue for another 24 weeks. The main goal is to see if more patients achieve a meaningful reduction in disease activity.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sirolimus (rapamycin)
What this could lead to
If successful, sirolimus could offer a new treatment option for people with active lupus that is not well controlled by current therapies.
What could go wrong
This is a mid-stage trial with 146 participants, so results may not apply to everyone. Sirolimus has known side effects like mouth sores, infections, and increased cholesterol.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100053, China
-
Shenzhen People's Hospital
Shenzhen, Guangdong, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China